About the Program:
Program Overview:
The Advances in Chronic Hepatitis C: Management and Treatment program
is a comprehensive, expert review of the 50th Annual Meeting of the European
Association for the Study of the Liver (EASL 2015). This program consists of
four components: (1) CME Internet
Symposium: EASL 2015 Review: a 1.5 hour Internet symposium that features an
overview and discussion of key presentations and posters, selected by the
expert faculty discussants; (2) CME
Internet Symposium: European Perspective on EASL 2015: a 1-hour Internet
symposium featuring Europe-based expert faculty reviewing and discussing key
presentations with a focus on management and treatment in the EU; (3) Rapid-Fire Review of EASL 2015: a
podcast that provides a brief, audio summary of the most essential data
presented at the conference; and (4) From
Conference to Clinic: Reviewing and Applying Data from EASL 2015:
case-based dinner meetings during which the key data are reviewed, discussed
and applied to patient care.
From Conference to
Clinic: Reviewing and Applying Data From EASL 2015 is an interactive, case-based
dinner program series designed to highlight and discuss the relative merits and
clinical significance of new findings in HCV medicine presented at EASL 2015. Since
the focus of the dinner programs will be on case studies and applying the data
presented at EASL 2015 in a clinical setting, prior to attending a dinner
program participants will be asked to view the CME Internet Symposium: EASL 2015 Review, which
will familiarize them with the EASL 2015 data and serve as a comprehensive conference
overview and summary. As a result of this blended learning approach,
participants will gain an increased understanding of key data presented at EASL
2015 and be better prepared to address their HCV patients’ health needs and
provide optimal care in a clinical setting.
All
online components of the program can be accessed at www.viraled.com.
This
program is produced by the Postgraduate Institute for Medicine and ViralEd,
Inc. It is not a session created by or presented at EASL 2015 and it is not
sanctioned by the organizers of EASL 2015.
Target Audience:
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.
Educational Objectives:
After completing this activity, the participant should be better able to:
- Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at EASL 2015
- Employ current treatment protocols for CHC in clinical practice, including the studies and data presented at EASL 2015, to improve patient care
- Engage patients and colleagues in a discussion on studies and data presented at EASL 2015 relevant to new therapies for CHC to determine the appropriate treatment for patients with CHC
Program Dates and Locations:
Thursday, April 30, 2015
Boston, MA
|
Wednesday, May 13, 2015
San Francisco, CA |
Wednesday, May 6, 2015
Los Angeles, CA |
Thursday, May 14, 2015
Miami, FL |
Thursday, May 7, 2015
Phoenix, AZ
|
Wednesday, May 20, 2015
Baltimore, MD
|
Thursday, May 7, 2015
New York, NY
|
Thursday, May 21, 2015
Chicago, IL
|
Tuesday, May 12, 2015
Houston, TX
|
Thursday, May 28, 2015
Detroit, MI
|
Program Faculty:
Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center
Beth Israel Deaconess Medical Center
Boston, Massachusetts
|
Maurizio Bonacini, MD
Director, HIV-Liver Clinic
Department of Transplantation
California Pacific Medical Center
San Francisco, California
|
Lennox Jeffers, MD
Chief of Hepatology
Miami VA Medical Center
Associate Chief
Center for Liver Disease
Professor of Medicine
University of Miami’s School of Medicine
Miami, Florida
|
Richard A. Manch, MD, FACP, FACG
Chief of Hepatology
St. Joseph’s Hospital and Medical Center
Clinical Professor of Medicine
Creighton University School of Medicine – Phoenix Regional Campus
Phoenix, Arizona
|
Sammy Saab, MD
Professor of Medicine and Surgery
The Pfleger Liver Institute
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
|
Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
|
John M. Vierling, MD
Professor of Medicine
Professor of Surgery
Chief of Hepatology
Director of Advanced Liver Therapies
St. Luke’s HospitalDirector of Baylor Liver Health
Houston, Texas |
|
Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Sunshine Act:
As of August 1, 2013, pharmaceutical companies are required by the open payments act (AKA Sunshine Act) to account for certain transfers of value provided to physicians. The federal guidance for the Sunshine Act provides exceptions for CME expenses that meet certain criteria. We believe the program to which you are invited meets these exce ptions, and therefore we will not be collecting, nor reporting, any information gathered from this program. If federal guidance is further clarified in the future, we will then pro vide that information to the supporting pharmaceutical companies to the best of our ability.
Disclosure of Conflicts of Interest:
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Supported by an independent educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
|